As Polpharma Group, we join the call for the European Union to take decisive action to conclude the pharmaceutical reform and strengthen Europe’s capacity to produce essential medicines. We advocate for early access to generics to optimize health payer budgets and enable treatments for more patients. In the face of unprecedented geopolitical uncertainty, it is crucial to place public health at the center of all political decisions.
Commitment to Health Security
We strongly believe, that public health is a fundamental right. As EU Health Ministries approach the final stages of negotiations on the future of Europe’s pharmaceutical rules, Polpharma Group emphasizes the need to ensure that every European has access to the medicines they need. This is about avoiding shortages, bringing production back to Europe, and making our health systems more resilient and fair.
Key Recommendations
- Reduced Periods of Exclusivities: On-patent pharmaceutical companies are pushing for extended exclusivities in Europe, which would hinder competition and delay access to affordable medicines.
- Timely Access: Early entry of off-patent medicines has been proven to save costs for health payers, with significant price reductions observed.
- Investment in EU Manufacturing: Ensuring medicines are manufactured in Europe to improve supply chain resilience.
We call the EU to resist attempts to derail the review of pharmaceutical legislation and back competition for the benefit of patients. It’s time for Europe to take responsibility, finalize the pharmaceutical reform, empower the Critical Medicines Act, and protect patients.